Date: 2015-09-04
Type of information: Nomination
Compound:
Company: Celyad (Belgium)
Therapeutic area: Cardiovascular diseases - Regenerative medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 4, 2015, Celyad announced the appointment of Debasish F. Roychowdhury as new independent non-executive director. Dr. Roychowdhury is a medical oncologist with over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research. In the pharmaceutical industry, Debasish held multiple positions of growing responsibility respectively at Eli Lilly, GSK and Sanofi, with direct therapeutic area experience mostly in oncology and hematology. Based in Boston, Massachusetts, Debasish is now using his extensive experience and global network to advise companies, organizations, and institutions in the biomedical field. Dr. Roychowdhury’s appointment was effective 21 August 2015. Debasish will be replacing Jean-Marc Heynderickx who stepped down from the Board.
Financial terms:
Latest news:
